* DarioHealth Corp DRIO.OQ DRIO.O is expected to show a
rise
in quarterly revenue when it reports results on November 7 for
the period ending September 30 2024
* The New York City-based company is expected to report a
110.3% increase in revenue to $7.397 million from $3.52 million
a year ago, according to the mean estimate from 3 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for DarioHealth Corp is for
a loss
of 27 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for DarioHealth
Corp
is 3.50, above its last closing price of $0.89.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.55 -0.55 -0.08 Beat 85.6
Jan. 1 2024 -0.48 -0.40 -0.20 Beat 50.6
Dec. 31 2023 -0.54 -0.55 -0.50 Beat 9.6
Sep. 30 2023 -0.48 -0.46 -0.49 Missed -6.5
Jan. -0.57 -0.52 -0.58 Missed -11.1
1 0001
Jan. 1 0001 -0.49 -0.50 -0.45 Beat 9.6
Dec. 31 2022 -0.56 -0.65 -0.51 Beat 21.8
Sep. 30 2022 -0.71 -0.76 -0.64 Beat 16.1
This summary was machine generated November 6 at 14:27 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)